Intended for healthcare professionals

Rapid response to:

Editorials

WHO downgrades status of oseltamivir

BMJ 2017; 358 doi: https://doi.org/10.1136/bmj.j3266 (Published 12 July 2017) Cite this as: BMJ 2017;358:j3266

Rapid Response:

Re: WHO downgrades status of oseltamivir

It is interesting to note that for a product with “$18bn in sales worldwide, half of it from governments stockpiling the drug”, in a disease that affects children, Roche has not yet completed the paediatric investigation plan, according to EMA records (http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/pips/EMEA-00...). This is after almost 8 years from the first agreement of the plan, during which Roche requested eight procedures of modification of the plan itself (http://www.ema.europa.eu/docs/en_GB/document_library/PIP_decision/WC5002...).

Competing interests: No competing interests

13 July 2017
Paolo Tomasi
Public servant
Edgware